Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non
Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.
How this was made
The 30-second read
Why it matters
Q2 shows strong YoY revenue growth but a revenue miss and slightly underwhelming next-quarter revenue guidance, while non-GAAP EPS beat and adjusted operating margin was relatively stable sequentially.
Market read
Traders can reassess near-term revenue expectations using the $1.02B next-quarter guidance and weigh it against the $0.80 non-GAAP EPS beat and stable adjusted operating margin.
What to watch
The article highlights adjusted operating margin deterioration over longer horizons; traders may focus on whether cost discipline can reverse that trend, not just the single-quarter print.
Background
Astrana Health (formerly Apollo Medical Holdings) runs a technology-powered healthcare platform focused on physician-centric, value-based care.
Ticker impact
Astrana Health reported Q2 CY2026 revenue of $972.5M (48.5% YoY) but guided next-quarter revenue to $1.02B, 1.1% below estimates.
Likely choppy trading, with upside support from the EPS beat and downside risk from the revenue guidance miss.
The article provides concrete Q2 results (revenue miss, EPS beat) and a specific next-quarter revenue guidance shortfall versus analysts, plus notes the stock rose 5.1% immediately after results.
Market effects
Signals continued demand strength in physician-centric, value-based healthcare services, but margin pressure remains a watch item.
No specific regional spillover described beyond US healthcare services sentiment.
Limited global relevance; story is company-specific within US healthcare services.
Counterpoint
The revenue guidance miss is small (1.1% below estimates) and EPS beat plus stable adjusted operating margin could outweigh the top-line concern.
Key entities
- companyAstrana Health
NASDAQ-listed healthcare services company reporting Q2 CY2026 results and next-quarter revenue guidance.
- executiveBrandon Sim
CEO who commented on Q2 results reflecting the company’s physician-centric, AI-native operating system.
